Our results suggest that differentially phosphorylated proteins could be considered as more promising markers of differentiation for NB than differentially expressed proteins.
In the present study, simultaneous expression of both forms of EGFR emerged as a more promising prognostic marker in invasive breast carcinomas.
The goal of preclinical exploratory studies is to identify one or more promising tumor markers which can then be further developed in subsequent stages of the pipeline.
In the studies performed to date, circulating cell-free nucleic acids seem to be among the more promising prognostic markers that could be used in severe sepsis.
More promising as a marker of neoplasia is vimentin promoter methylation, which is being evaluated as a candidate marker of colorectal carcinomas (Chen et al, 2005; Zou et al, 2007; Shirahata et al, 2009).
However, using LSP derived from techniques such as logistic curve modeling for extracting seasonal markers appears more promising.
Therefore, in this study, we proposed that integrative analysis of these two types of genetic markers (SNP and GE markers) may provide a more promising alternative for construction of a high-accuracy and cost-beneficial AIM panel than analysis of SNP or GE markers alone.
The adjunction of the SSRI, however, results in a dramatic potentiation of the markers amplitude, suggesting an even more promising clinical perspective.
Topo2a amplification seems to be more promising biomarker of MBC survival, than HER2, and potential marker of resistance to CMF therapy.
Hopefully, the search for other tumour markers, for instance by proteomics, will generate more promising alternatives.
